Annual Report

The report describes Pharming's 2022 financial growth, with revenues of US$205.6 million and operating profit of US$18.2 million. Year-end employment increased to 390 people from 321 in 2021. Pharming also established an ESG steering committee and launched an ESG program during the year. The report further records the subsequent U.S. FDA approval of Joenja on March 24, 2023, following regulatory progress during 2022.